Nodal TFH cell lymphoma, angioimmunoblastic-type

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search

Haematolymphoid Tumours (5th ed.)

editHAEM5 Conversion Notes
This page was converted to the new template on 2023-12-07. The original page can be found at HAEM4:Angioimmunoblastic T-cell Lymphoma.

(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use HUGO-approved gene names and symbols (italicized when appropriate), HGVS-based nomenclature for variants, as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see Author_Instructions and FAQs as well as contact your Associate Editor or Technical Support)

Primary Author(s)*

  • Sara Akhavanfard, M.D., Ph.D.
  • Ruthann Pfau, Ph.D., FACMG

Cancer Category / Type

Cancer Sub-Classification / Subtype

  • Angioimmunoblastic T-cell Lymphoma (AITL)

Definition / Description of Disease

  • A neoplasm of mature T follicular helper (TFH) cells
  • Characterized by systemic disease and a polymorphous infiltrate involving lymph nodes
  • Have prominent proliferation of high endothelial venules (HEVs) and follicular dendritic cells (FDCs)
  • EBV-positive B cells are nearly always present
  • Clinically aggressive and seen mainly in older adults


editUnassigned References
The following referenees were placed in the header. Please place them into the appropriate locations in the text.

[1]

Synonyms / Terminology

  • Peripheral T-cell Lymphoma
  • Angioimmunoblastic Lymphadenopathy with Dysproteinaemia
  • Immunoblastic Lymphadenopathy
  • Lymphogranulomatosis X

Epidemiology / Prevalence

  • Occurs in middle-aged and elderly individuals[2]
  • Males >> Females[2]
  • One of the most common specific subtypes of PTCL[3][4][5]
    • 15-30% of non-cutaneous T-cell lymphomas
    • 1-2% of all non-Hodgkin lymphomas

Clinical Features

Put your text here and fill in the table (Instruction: Can include references in the table)

Signs and Symptoms EXAMPLE Asymptomatic (incidental finding on complete blood counts)

EXAMPLE B-symptoms (weight loss, fever, night sweats)

EXAMPLE Fatigue

EXAMPLE Lymphadenopathy (uncommon)

Laboratory Findings EXAMPLE Cytopenias

EXAMPLE Lymphocytosis (low level)


editv4:Clinical Features
The content below was from the old template. Please incorporate above.

Sign and Symptoms

  • Advanced-stage disease with systemic symptoms
  • Generalized lymphadenopathy
  • Hepatosplenomegaly
  • Polyclonal hypergammaglobulinemia
  • Skin rash, often with pruritus
  • Pleural effusion
  • Arthritis
  • Ascites

Laboratory Findings

  • Circulating Immune Complexes
  • Cold agglutinins with haemolytic anemia
  • Positive rheumatoid factor
  • Positive anti-smooth muscle antibody


editUnassigned References
The following referenees were placed in the header. Please place them into the appropriate locations in the text.

[6][7][8][9]

Sites of Involvement

  • Primary site: Lymph node
  • Other involved sites: Spleen, Liver, Skin,and Bone marrow[10][11][12][13]

Morphologic Features

Pattern-1 (Early involvement)

  • Bare, hyperplastic follicles, with Well-formed germinal centers, often lacking well-defined mantle cuffs[14]
  • Paracortical expansion
  • Marked Vascular Proliferation, associated with perifollicular or atypical lymphoid cells

Pattern-2

  • Remnant of follicles with regressive changes
  • Readily identified neoplastic cells in the expanded paracortex
  • Marked perifollicular expansion of clear cells

Pattern-3

  • Totally or sub-totally effacement of normal architecture
  • Marked vascular proliferation
  • Aggregates of atypical lymphoid cells


editUnassigned References
The following referenees were placed in the header. Please place them into the appropriate locations in the text.

[15][16]

Immunophenotype

Finding Marker
Positive (universal) CD2, CD3, CD4, CD5, CD10, CXCL13, ICOS, BCL6, PD1(CD279)
Positive (extrafollicular pattern) CD21, CD23, CD35


editUnassigned References
The following referenees were placed in the header. Please place them into the appropriate locations in the text.

[17][18][19][20][21]

Chromosomal Rearrangements (Gene Fusions)

Put your text here and fill in the table

Chromosomal Rearrangement Genes in Fusion (5’ or 3’ Segments) Pathogenic Derivative Prevalence Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE t(9;22)(q34;q11.2) EXAMPLE 3'ABL1 / 5'BCR EXAMPLE der(22) EXAMPLE 20% (COSMIC)

EXAMPLE 30% (add reference)

Yes No Yes EXAMPLE

The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).


editv4:Chromosomal Rearrangements (Gene Fusions)
The content below was from the old template. Please incorporate above.
Chromosomal Rearrangement Genes in Fusion (5’ or 3’ Segments) Pathogenic Derivative Reference
t(5;9)(q33;q22) ITK/SYK der(5); der(9) [22][23]
t(7;14)(q35;q32.1) TRB/TCL1A der(7); der(14) [24]
t(14;14)(q11;q32.1) / inv(14)(q11q32.1) TRA-TRD/TCL1A der(14) [25][26]
chr(2)(q33.2) CTLA4/CD28 der(2) [27]


editv4:Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications).
Please incorporate this section into the relevant tables found in:
  • Chromosomal Rearrangements (Gene Fusions)
  • Individual Region Genomic Gain/Loss/LOH
  • Characteristic Chromosomal Patterns
  • Gene Mutations (SNV/INDEL)
  • Overall prognosis is poor[28][29]
  • Median survival < 3 years, even with aggressive treatment[28][29]
  • Male sex, mediastinal lymphadenopathy, and anemia adversely affect the survival[28]

Suggested Treatment Regimens based on NCCN Guideline Version 1.2020 (TCEL-B 3 of 5)

Second-line therapy (with intention to transplant) and subsequent therapy:

  • Clinical Trial preferred
  • Preferred regimens
    • Single Agents (alphabetical order)
      • Belinostat
      • Brentuximab Vedotin for CD30+ AITL
      • Romidepsin
    • Combination Regimens
      • DHAP(Dexamethasone, Cisplatin, Cytarabine)
      • ESHAP (Etoposide, Methylprednisolone, Citarabine, Cisplatin)
      • GDP (Gemcitabine, Dexamethasone, Cisplatin)
      • GemOx (Gemcitabine, Oxaliplatin)
      • ICE (Ifosfamide, Carboplatin, Etoposide)
  • Other recommended regimens
    • Single Agents (alphabetical order)
      • Bendamustine
      • Gemcitabine
      • Lenalidomide
      • Pralatrexate

Second-line or initial palliative intent therapy (no intention to transplant) and subsequent therapy:

  • Clinical Trial preferred
  • Preferred regimens
    • Single Agents (alphabetical order)
      • Belinostat
      • Brentuximab Vedotin for CD30+ AITL
      • Romidepsin
  • Other recommended regimen (alphabetical order)
    • Alemtuzumab
    • Bendamustine
    • Bertezomib (categort 2B)
    • Cyclophosphamide and/or Etoposide (IV or PO)
    • Cyclosporine
    • Gemcitabine
    • Lenalidomide
    • Pralatrexate
    • Radiation therapy

Individual Region Genomic Gain / Loss / LOH

Put your text here and fill in the table (Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.)

Chr # Gain / Loss / Amp / LOH Minimal Region Genomic Coordinates [Genome Build] Minimal Region Cytoband Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE

7

EXAMPLE Loss EXAMPLE

chr7:1- 159,335,973 [hg38]

EXAMPLE

chr7

Yes Yes No EXAMPLE

Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).

EXAMPLE

8

EXAMPLE Gain EXAMPLE

chr8:1-145,138,636 [hg38]

EXAMPLE

chr8

No No No EXAMPLE

Common recurrent secondary finding for t(8;21) (add reference).

editv4:Genomic Gain/Loss/LOH
The content below was from the old template. Please incorporate above.
Chromosome Number Gain/Loss/Amp/LOH Reference
3,5,21 Trisomy [30]
X Gain [30]
6q Loss [30]
22q Gain [31]
19 Gain [31]
11q13 Gain [31]
13q Loss [31]

Characteristic Chromosomal Patterns

Put your text here (EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis)

Chromosomal Pattern Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE

Co-deletion of 1p and 18q

Yes No No EXAMPLE:

See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).

editv4:Characteristic Chromosomal Aberrations / Patterns
The content below was from the old template. Please incorporate above.
  • Clonal rearrangement in T-Cell receptor gene in 75-90% of AITL cases[32] [33][34]
  • Clonal rearrangement in immunoglobulin genes in 25-30% of AITL cases[32][34]

Gene Mutations (SNV / INDEL)

Put your text here and fill in the table (Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.)

Gene; Genetic Alteration Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other) Prevalence (COSMIC / TCGA / Other) Concomitant Mutations Mutually Exclusive Mutations Diagnostic Significance (Yes, No or Unknown) Prognostic Significance (Yes, No or Unknown) Therapeutic Significance (Yes, No or Unknown) Notes
EXAMPLE: TP53; Variable LOF mutations

EXAMPLE:

EGFR; Exon 20 mutations

EXAMPLE: BRAF; Activating mutations

EXAMPLE: TSG EXAMPLE: 20% (COSMIC)

EXAMPLE: 30% (add Reference)

EXAMPLE: IDH1 R123H EXAMPLE: EGFR amplification EXAMPLE:  Excludes hairy cell leukemia (HCL) (add reference).


Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.


editv4:Gene Mutations (SNV/INDEL)
The content below was from the old template. Please incorporate above.
Gene Mutation‡ Oncogene/Tumor Suppressor/Other Presumed Mechanism

(LOF/GOF/Other; Driver/Passenger)

Prevalence

(COSMIC/TCGA/Other)

IDH2 R172S; R172G;R172K Tumor Suppressor ONCOGENE LOF GOF 20-30%[35][23][36][37]
TET2 Widely distributed Tumor Suppressor LOF 50-80%[38][36]
DNMT3A W305* Tumor Suppressor LOF 20-30%[23][36]
RHOA G17V; G17E; C16R; T19I; D120Y Tumor Suppressor ONCOGENE LOF GOF 60-70%[39][40][41]
FYN L174R; R176C; Y531H Oncogene GOF up to 5-10%[42][41]
PLCG1 S345F; G869E Oncogene GOF up to 5-10%[42][23]
CD28 D124V; D124E; T195P Oncogene GOF up to 5-10%[42][43]
TNFRSF21 S428fs*S1 Tumor Suppressor LOF [23]
CCND3 Q280* Tumor Suppressor LOF [23]
SAMSN1 R153* Tumor Suppressor LOF [23]

‡More comprehensive account of specific mutations in these genes can be found in cBioPortal and COSMIC.

Epigenomic Alterations

  • Frequent mutation in epigenetic modifiers like: [23][36][37][38]
    • IDH2 (20-30%)
    • TET2 (50-80%)
    • DNMT3A (20-30%)

Genes and Main Pathways Involved

Put your text here and fill in the table (Instructions: Can include references in the table.)

Gene; Genetic Alteration Pathway Pathophysiologic Outcome
EXAMPLE: BRAF and MAP2K1; Activating mutations EXAMPLE: MAPK signaling EXAMPLE: Increased cell growth and proliferation
EXAMPLE: CDKN2A; Inactivating mutations EXAMPLE: Cell cycle regulation EXAMPLE: Unregulated cell division
EXAMPLE:  KMT2C and ARID1A; Inactivating mutations EXAMPLE:  Histone modification, chromatin remodeling EXAMPLE:  Abnormal gene expression program
editv4:Genes and Main Pathways Involved
The content below was from the old template. Please incorporate above.
Molecular Features Pathway Pathophysiologic Outcome
FYN, PLCG1, and CD28 mutations T-cell receptor signaling pathway[23][41][42][43] Increased proliferation and survival
IDH2, TET2, and DNMT3A mutations Histone modification and chromatin remodeling[23][36][37][38] Abnormal gene expression program

Genetic Diagnostic Testing Methods

  • Clinical, morphological, and immunophenotypic findings are generally sufficient for diagnosis
  • IDH2 R172 mutations are specific to AITL
  • T-Cell receptor and immunoglobulin genes rearrangement detection by karyotyping and FISH analysis

Familial Forms

Put your text here (Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.)

Additional Information

N/A

Links

HAEM4:Angioimmunoblastic T-cell Lymphoma and Other Nodal Lymphomas of T Follicular Helper Cell Origin

References

(use the "Cite" icon at the top of the page) (Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference.)

  1. ↑ Dogan A, et al., (2017). Angioimmunoblastic T-cell Lymphoma, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p407-411.
  2. ↑ 2.0 2.1 L, de Leval; et al. (2010). "Advances in the understanding and management of angioimmunoblastic T-cell lymphoma". PMID 19961485.
  3. ↑ M, Vences; et al. (2013). "To name or not to name: Criteria to promote economy of change in Linnaean classification schemes". PMID 26042291.
  4. ↑ T, Rüdiger; et al. (2002). "Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project". PMID 11863096.
  5. ↑ J, Vose; et al. (2008). "International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes". PMID 18626005.
  6. ↑ A, Dogan; et al. (2003). "Angioimmunoblastic T-cell lymphoma". PMID 12780782.
  7. ↑ F, Lachenal; et al. (2007). "Angioimmunoblastic T-cell lymphoma: clinical and laboratory features at diagnosis in 77 patients". PMID 17873758.
  8. ↑ N, Mourad; et al. (2008). "Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials". doi:10.1182/blood-2007-08-105759. PMC 2343588. PMID 18292286.CS1 maint: PMC format (link)
  9. ↑ W, Siegert; et al. (1995). "Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group". PMID 8664186.
  10. ↑ L, de Leval; et al. (2010). "Advances in the understanding and management of angioimmunoblastic T-cell lymphoma". PMID 19961485.
  11. ↑ A, Dogan; et al. (2003). "Angioimmunoblastic T-cell lymphoma". PMID 12780782.
  12. ↑ M, Federico; et al. (2013). "Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the international peripheral T-cell lymphoma project". doi:10.1200/JCO.2011.37.3647. PMC 3532394. PMID 22869878.CS1 maint: PMC format (link)
  13. ↑ N, Mourad; et al. (2008). "Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials". doi:10.1182/blood-2007-08-105759. PMC 2343588. PMID 18292286.CS1 maint: PMC format (link)
  14. ↑ Hj, Ree; et al. (1998). "Angioimmunoblastic lymphoma (AILD-type T-cell lymphoma) with hyperplastic germinal centers". PMID 9630171.
  15. ↑ A, Attygalle; et al. (2002). "Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10". PMID 11781247.
  16. ↑ M, Rodriguez-Justo; et al. (2009). "Angioimmunoblastic T-cell lymphoma with hyperplastic germinal centres: a neoplasia with origin in the outer zone of the germinal centre? Clinicopathological and immunohistochemical study of 10 cases with follicular T-cell markers". PMID 19329936.
  17. ↑ A, Attygalle; et al. (2002). "Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10". PMID 11781247.
  18. ↑ L, de Leval; et al. (2007). "The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells". PMID 17284527.
  19. ↑ Dm, Dorfman; et al. (2006). "Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma". doi:10.1097/01.pas.0000209855.28282.ce. PMC 3137919. PMID 16819321.CS1 maint: PMC format (link)
  20. ↑ Kl, Grogg; et al. (2005). "Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells?". doi:10.1182/blood-2005-03-1083. PMC 1895208. PMID 16079436.CS1 maint: PMC format (link)
  21. ↑ G, Roncador; et al. (2007). "Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma". PMID 17640856.
  22. ↑ B, Streubel; et al. (2006). "Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma". PMID 16341044.
  23. ↑ 23.0 23.1 23.2 23.3 23.4 23.5 23.6 23.7 23.8 23.9 M, Wang; et al. (2017). "Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling". doi:10.18632/oncotarget.14846. PMC 5392284. PMID 28148900.CS1 maint: PMC format (link)
  24. ↑ Mf, Cosimi; et al. (1990). "Rearrangements on chromosomes 7 and 14 with breakpoints at 7q35 and 14q11 in angioimmunoblastic lymphadenopathy and IBL-like T-cell lymphoma". PMID 2284141.
  25. ↑ B, Schlegelberger; et al. (1990). "Inv(14)(q11q32) in one of four different clones in a case of angioimmunoblastic lymphadenopathy". PMID 2293883.
  26. ↑ E, Leich; et al. (2007). "Tissue microarray-based screening for chromosomal breakpoints affecting the T-cell receptor gene loci in mature T-cell lymphomas". PMID 17582237.
  27. ↑ Hy, Yoo; et al. (2016). "Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma". doi:10.3324/haematol.2015.139253. PMC 5013939. PMID 26819049.CS1 maint: PMC format (link)
  28. ↑ 28.0 28.1 28.2 N, Mourad; et al. (2008). "Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials". doi:10.1182/blood-2007-08-105759. PMC 2343588. PMID 18292286.CS1 maint: PMC format (link)
  29. ↑ 29.0 29.1 J, Vose; et al. (2008). "International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes". PMID 18626005.
  30. ↑ 30.0 30.1 30.2 B, Schlegelberger; et al. (1994). "Detection of aberrant clones in nearly all cases of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined interphase and metaphase cytogenetics". PMID 7919378.
  31. ↑ 31.0 31.1 31.2 31.3 C, Thorns; et al. (2007). "Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: A matrix-based CGH approach". PMID 17044049.
  32. ↑ 32.0 32.1 Ad, Attygalle; et al. (2007). "Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics". PMID 17448026.
  33. ↑ L, de Leval; et al. (2010). "Advances in the understanding and management of angioimmunoblastic T-cell lymphoma". PMID 19961485.
  34. ↑ 34.0 34.1 Bt, Tan; et al. (2006). "The frequency of B- and T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations". doi:10.2353/jmoldx.2006.060016. PMC 1867616. PMID 16931587.CS1 maint: PMC format (link)
  35. ↑ Ra, Cairns; et al. (2012). "IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma". doi:10.1182/blood-2011-11-391748. PMC 3293643. PMID 22215888.CS1 maint: PMC format (link)
  36. ↑ 36.0 36.1 36.2 36.3 36.4 O, Odejide; et al. (2014). "A targeted mutational landscape of angioimmunoblastic T-cell lymphoma". doi:10.1182/blood-2013-10-531509. PMC 4260974. PMID 24345752.CS1 maint: PMC format (link)
  37. ↑ 37.0 37.1 37.2 C, Wang; et al. (2015). "IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma". doi:10.1182/blood-2015-05-644591. PMC 4600014. PMID 26268241.CS1 maint: PMC format (link)
  38. ↑ 38.0 38.1 38.2 F, Lemonnier; et al. (2012). "Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters". PMID 22760778.
  39. ↑ M, Sakata-Yanagimoto; et al. (2014). "Somatic RHOA mutation in angioimmunoblastic T cell lymphoma". PMID 24413737.
  40. ↑ Hy, Yoo; et al. (2014). "A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma". PMID 24584070.
  41. ↑ 41.0 41.1 41.2 T, Palomero; et al. (2014). "Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas". doi:10.1038/ng.2873. PMC 3963408. PMID 24413734.CS1 maint: PMC format (link)
  42. ↑ 42.0 42.1 42.2 42.3 Sh, Lee; et al. (2015). "A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients". doi:10.3324/haematol.2015.133074. PMC 4666342. PMID 26405154.CS1 maint: PMC format (link)
  43. ↑ 43.0 43.1 J, Rohr; et al. (2016). "Recurrent activating mutations of CD28 in peripheral T-cell lymphomas". doi:10.1038/leu.2015.357. PMC 5688878. PMID 26719098.CS1 maint: PMC format (link)

Notes

*Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome. *Citation of this Page: “Nodal TFH cell lymphoma, angioimmunoblastic-type”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated 12/13/2023, https://ccga.io/index.php/HAEM5:Nodal_TFH_cell_lymphoma,_angioimmunoblastic-type.

Retrieved from "https://ccga.io/index.php?title=HAEM5:Nodal_TFH_cell_lymphoma,_angioimmunoblastic-type&oldid=13808"